Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen

A Isaac; S Taylor; Patricia Cane; E Smit; SE Gihbons; DJ White; SM Drake; S Khoo; DJ Back

doi:10.1093/jac/dkh357

Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen

A Isaac, S Taylor, Patricia Cane, E Smit, SE Gihbons, DJ White, SM Drake, S Khoo, DJ Back

Research output: Contribution to journal › Article

28 Citations (Scopus)

Abstract

Objectives: To evaluate the steady-state blood plasma (BP), CSF and seminal plasma (SP) pharmacokinetics (PK) of twice-daily indinavir 400 mg and lopinavir/ritonavir. Methods: Ten HIV-1-positive men on lopinavir/ritonavir participated in a PK study. PK sampling was performed before and 2 weeks after adding indinavir to lopinavir/ritonavir-containing regimens. BP, CSF and SP RNA levels, CD4 counts and blood chemistry were checked at baseline and 2 weeks after indinavir. Results: At baseline: lopinavir parameters (n=10) in BP were within expected levels. Median lopinavir trough concentrations (n=5) in CSF and SP were below the limit of detection (BLD) (i.e. 80 ng/mL in seven of eight plasma samples, and all CSF and semen samples collected.

Original language	English
Pages (from-to)	498-502
Number of pages	5
Journal	Journal of Antimicrobial Chemotherapy
Volume	54
Issue number	2
DOIs	https://doi.org/10.1093/jac/dkh357
Publication status	Published - 1 Aug 2004

Keywords

drug interactions
double boosted
protease inhibitors
HIV
sanctuary sites

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkh357

Cite this

@article{7ea1f3800a87468c99cbbbd03a0ea2c3,

title = "Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen",

abstract = "Objectives: To evaluate the steady-state blood plasma (BP), CSF and seminal plasma (SP) pharmacokinetics (PK) of twice-daily indinavir 400 mg and lopinavir/ritonavir. Methods: Ten HIV-1-positive men on lopinavir/ritonavir participated in a PK study. PK sampling was performed before and 2 weeks after adding indinavir to lopinavir/ritonavir-containing regimens. BP, CSF and SP RNA levels, CD4 counts and blood chemistry were checked at baseline and 2 weeks after indinavir. Results: At baseline: lopinavir parameters (n=10) in BP were within expected levels. Median lopinavir trough concentrations (n=5) in CSF and SP were below the limit of detection (BLD) (i.e. 80 ng/mL in seven of eight plasma samples, and all CSF and semen samples collected.",

keywords = "drug interactions, double boosted, protease inhibitors, HIV, sanctuary sites",

author = "A Isaac and S Taylor and Patricia Cane and E Smit and SE Gihbons and DJ White and SM Drake and S Khoo and DJ Back",

year = "2004",

month = aug,

day = "1",

doi = "10.1093/jac/dkh357",

language = "English",

volume = "54",

pages = "498--502",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "1460-2091",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen

AU - Isaac, A

AU - Taylor, S

AU - Cane, Patricia

AU - Smit, E

AU - Gihbons, SE

AU - White, DJ

AU - Drake, SM

AU - Khoo, S

AU - Back, DJ

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Objectives: To evaluate the steady-state blood plasma (BP), CSF and seminal plasma (SP) pharmacokinetics (PK) of twice-daily indinavir 400 mg and lopinavir/ritonavir. Methods: Ten HIV-1-positive men on lopinavir/ritonavir participated in a PK study. PK sampling was performed before and 2 weeks after adding indinavir to lopinavir/ritonavir-containing regimens. BP, CSF and SP RNA levels, CD4 counts and blood chemistry were checked at baseline and 2 weeks after indinavir. Results: At baseline: lopinavir parameters (n=10) in BP were within expected levels. Median lopinavir trough concentrations (n=5) in CSF and SP were below the limit of detection (BLD) (i.e. 80 ng/mL in seven of eight plasma samples, and all CSF and semen samples collected.

AB - Objectives: To evaluate the steady-state blood plasma (BP), CSF and seminal plasma (SP) pharmacokinetics (PK) of twice-daily indinavir 400 mg and lopinavir/ritonavir. Methods: Ten HIV-1-positive men on lopinavir/ritonavir participated in a PK study. PK sampling was performed before and 2 weeks after adding indinavir to lopinavir/ritonavir-containing regimens. BP, CSF and SP RNA levels, CD4 counts and blood chemistry were checked at baseline and 2 weeks after indinavir. Results: At baseline: lopinavir parameters (n=10) in BP were within expected levels. Median lopinavir trough concentrations (n=5) in CSF and SP were below the limit of detection (BLD) (i.e. 80 ng/mL in seven of eight plasma samples, and all CSF and semen samples collected.

KW - drug interactions

KW - double boosted

KW - protease inhibitors

KW - HIV

KW - sanctuary sites

U2 - 10.1093/jac/dkh357

DO - 10.1093/jac/dkh357

M3 - Article

C2 - 15254024

SN - 1460-2091

VL - 54

SP - 498

EP - 502

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 2

ER -

Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this